Citations

Showing 10 of 108094 citations.

Health Care Utilization in Systemic Lupus Erythematosus in the Community
Figueroa‐Parra, Gabriel , Valenzuela-Almada, Maria O , Vallejo, Sebastián , Osei‐Onomah, Shirley‐Ann, Giblon, Rachel , Dabit, Jesse Y. , Greenlund, Kurt J. , Crowson, Cynthia S. , Osei-Onomah, Shirley-Ann, Giblon, Rachel E., Figueroa-Parra, Gabriel , Chevet, Baptiste , Hocaoǧlu, Mehmet , Chamberlain, Alanna M. , Cornec, Divi , Barbour, Kamil E , Duarte‐García, Alí

Mayo Clinic

JCR: Journal of Clinical Rheumatology | October 17, 2022 | Volume: 29 | Issue: 1 | Pages: 29-35

10.1097/rhu.0000000000001899 | PMID 36251449 Get It

Objective The aim of this study was to determine inpatient health care utilization in an incident cohort of patients with systemic lupus erythematosus (SLE) compared with the general population. Methods This was a population-based cohort study in the upper Midwest, United States. We included patients fulfilling the European League Against Rheumatism/American College of Rheumatology SLE classification criteria between 1995 and 2018. They were 1:1 age-, sex-, county-matched with individuals without SLE. All hospital admissions and emergency department (ED) visits were electronically retrieved for 1995–2020. Rates for hospital admission, length of stay, readmission, ED visits, and discharge destination were compared between groups. Results Three hundred forty-one patients with SLE and 341 comparators without SLE were included (mean age, 48.6 years at diagnosis; 79.2% female). Rates of hospitalization for patients with SLE and comparators were 29.8 and 9.9 per 100 person-years, respectively. These differences were present across sexes and age groups. Hospitalization rates were higher in patients with SLE after diagnosis and remained higher than comparators for the first 15 years of the disease. Patients with SLE were more likely than comparators to visit the ED (hazard ratio, 2.71; 95% confidence interval, 2.05–3.59). Readmission rates (32% vs. 21%, p = 0.017) were higher in patients with SLE. Length of stay and discharge destination were similar between both groups. Conclusion Patients with SLE were more likely to be hospitalized and to visit the ED than individuals without SLE, highlighting important inpatient care needs. Increased hospitalization rates were observed in both male and female patients and all age groups.
Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data
Wymer, Kevin , Sharma, Vidit , Borah, Bijan J. , Costello, Brian A. , Pagliaro, Lance C. , Boorjian, Stephen A. , Joyce, Daniel D , Moriarty, James P. , Borah, Bijan J , Joyce, Daniel , Geynisman, Daniel M. , Plimack, Elizabeth R.

Mayo Clinic

Cancer | October 17, 2022 | Volume: 128 | Issue: 24 | Pages: 4194-4202

10.1002/cncr.34502 | PMID 36251574 Get It

AbstractBackgroundThe VESPER trial demonstrated improved progression‐free (PFS) and (preliminarily) overall survival (OS) with six cycles of neoadjuvant dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVACx6) versus four cycles of gemcitabine and cisplatin (GCx4) before radical cystectomy (RC) for muscle‐invasive bladder cancer (MIBC), but with increased toxicity. This study compares the cost‐effectiveness of these regimens.MethodsA cost‐effectiveness analysis of neoadjuvant ddMVACx6 and GCx4 was performed using a decision‐analytic Markov model with 5‐year, 10‐year, and lifetime horizons. Probabilities were derived from reported VESPER data. Utility values were obtained from the literature. Primary outcomes were effectiveness measured in quality‐adjusted life years (QALY) and incremental cost‐effectiveness ratio (ICER) with a willingness to pay threshold of $100,000 per QALY. One‐way and probabilistic sensitivity analyses were performed to evaluate the robustness of the model.ResultsAt 5 years, ddMVACx6 improved QALYs by 0.30 at an additional cost of $16,100, rendering it cost‐effective relative to GCx4 (ICER: $53,284/QALY). Additionally, probabilistic sensitivity analysis found ddMVACx6 to be cost‐effective in 79% and 81% of microsimulations at10‐year and lifetime horizons, respectively. One‐way sensitivity analysis demonstrated a minimum difference in 5‐year progression of 0.9% and progression mortality of 0.7% between ddMVACx6 and GCx4 was necessary for ddMVACx6 to remain cost‐effective.ConclusionsNeoadjuvant ddMVACx6 was more cost‐effective than GCx4 for MIBC. These data, together with the improved PFS and (albeit preliminary) OS noted in VESPER, support use of this regimen in appropriate candidates for neoadjuvant chemotherapy before RC.Lay summary We performed a benefit‐to‐cost analysis using evidence from a randomized controlled trial that compared two different chemotherapy treatments before bladder removal for bladder cancer that had invaded into the bladder muscle. Despite being more expensive and having a greater likelihood of toxicity, six cycles of dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin was more cost‐effective (or had higher value) than four cycles of gemcitabine and cisplatin.
Tachyarrhythmias During Hospitalization for COVID‐19 or Multisystem Inflammatory Syndrome in Children and Adolescents
Dionne, Audrey , Friedman, Kevin G. , Young, Cameron C. , Newhams, Margaret M. , Kücükak, Suden, Jackson, A. , Smallcomb, Laura , Heidemann, Sabrina M. , McLaughlin, Gwenn E., Irby, Katherine , Bradford, Tamara T. , Horwitz, Steven M. , Loftis, Laura L. , Soma, Vijaya L, Rowan, Courtney M. , Kong, Michele , Halasa, Natasha , Tarquinio, Keiko M. , Schwarz, Adam J. , Hume, Janet R. , Gertz, Shira J. , Clouser, Katharine N. , Carroll, Christopher L. , Wellnitz, Kari , Cullimore, Melissa L. , Doymaz, Sule , Levy, Emily R. , Lansell, Amanda , Butler, Andrew , Kuebler, Joseph D. , Zambrano, Laura D. , Campbell, Angela P. , Patel, Manish M. , Randolph, Adrienne G. , Investigators, for the Overcoming COVID‐19, Graciano, Ana Lía , Smallcomb, Laura S , Heidemann, Sabrina , Bradford, Tamara T , Rowan, Courtney M , Kong, Michele , Tarquinio, Keiko M , Hume, Janet R , Cullimore, Melissa L , Levy, Emily R , Lansell, Amanda N , Butler, Andrew D , Kuebler, Joseph D , Zambrano, Laura D , Campbell, Angela P , Randolph, Adrienne G , Newburger, Jane W , Young, Cameron C , Gertz, Shira J , Jackson, Ashley M., Fitzgerald, Julie C. , Typpo, Katri , Newburger, Jane W. , Investigators, for the Overcoming COVID‐19

Mayo Clinic

Journal of the American Heart Association | October 17, 2022 | Volume: 11 | Issue: 20 | Pages: No page available

10.1161/jaha.122.025915 | PMID 36250670 Get It

Background Cardiac complications related to COVID‐19 in children and adolescents include ventricular dysfunction, myocarditis, coronary artery aneurysm, and bradyarrhythmias, but tachyarrhythmias are less understood. The goal of this study was to evaluate the frequency, characteristics, and outcomes of children and adolescents experiencing tachyarrhythmias while hospitalized for acute severe COVID‐19 or multisystem inflammatory syndrome in children. Methods and Results This study involved a case series of 63 patients with tachyarrhythmias reported in a public health surveillance registry of patients aged <21 years hospitalized from March 15, 2020, to December 31, 2021, at 63 US hospitals. Patients with tachyarrhythmias were compared with patients with severe COVID‐19–related complications without tachyarrhythmias. Tachyarrhythmias were reported in 22 of 1257 patients (1.8%) with acute COVID‐19 and 41 of 2343 (1.7%) patients with multisystem inflammatory syndrome in children. They included supraventricular tachycardia in 28 (44%), accelerated junctional rhythm in 9 (14%), and ventricular tachycardia in 38 (60%); >1 type was reported in 12 (19%). Registry patients with versus without tachyarrhythmia were older (median age, 15.4 [range, 10.4–17.4] versus 10.0 [range, 5.4–14.8] years) and had higher illness severity on hospital admission. Intervention for treatment of tachyarrhythmia was required in 37 (59%) patients and included antiarrhythmic medication (n=31, 49%), electrical cardioversion (n=11, 17%), cardiopulmonary resuscitation (n=8, 13%), and extracorporeal membrane oxygenation (n=9, 14%). Patients with tachyarrhythmias had longer hospital length of stay than those who did not, and 9 (14%) versus 77 (2%) died. Conclusions Tachyarrhythmias were a rare complication of acute severe COVID‐19 and multisystem inflammatory syndrome in children and adolescents and were associated with worse clinical outcomes, highlighting the importance of close monitoring, aggressive treatment, and postdischarge care.
Mitral Valve Surgery for Persistent or Recurrent Mitral Regurgitation After Transcatheter Edge‐to‐Edge Repair Is Associated With Improved Survival
Shaer, Ahmed El , Ponce, Alejandra Chavez , Mazur, Piotr , Greason, Kevin L. , Arghami, Arman , Eleid, Mackram F. , Guerrero, Mayra , Rihal, Charanjit S. , Crestanello, Juan A. , Alkhouli, Mohamad , El Shaer, Ahmed , Chavez Ponce, Alejandra , Greason, Kevin , Alkhouli, Mohamad , Guerrero, Mayra E , Arghami, Arman , Crestanello, Juan A , Mazur, Piotr K , Rihal, Charanjit S.

Mayo Clinic

Journal of the American Heart Association | October 17, 2022 | Volume: 11 | Issue: 20 | Pages: No page available

10.1161/jaha.122.026236 | PMID 36250668 Get It

Background The management of severe mitral regurgitation (MR) after transcatheter edge‐to‐edge repair (TEER) remains a clinical conundrum. Considering the growing volume of TEER, more outcomes data for mitral surgery in this cohort are needed. Methods and Results Symptomatic patients with persistent or recurrent severe MR after TEER evaluated between May 2014 and June 2021 were included. The primary outcome was all‐cause mortality in patients who were treated with surgery versus medical therapy. The Kaplan–Meier and Cox regression methods were used to report risk‐adjusted survival analyses. Among the 142 included patients, 44 (31.0%) underwent mitral surgery. Patients who underwent surgery were younger than those treated medically (74.1±8.9 versus 78.6±10.5 years, P =0.01). Major comorbidities were similar except obesity, sleep apnea, left ventricular dimensions, and ejection fraction. Society of Thoracic Surgeons Predicted Risk of Operative Mortality was 9.0±4.7 versus 7.9±4.9 in the surgical versus medical therapy groups, respectively, P =0.22. Time from TEER to detection of severe MR was similar in both groups (median [interquartile range] 97.5 [39.5–384] versus 93.5 [40–389] days in the surgical versus medical groups, respectively [ P >0.05]). In the surgical group, valve replacement was performed in all patients. Operative mortality was 4.5% (observed/expected ratio 0.55), and major complications were uncommon. After risk‐adjustment, surgery was associated with significantly lower all‐cause mortality (adjusted hazard ratio, 0.33 [95% CI, 0.12–0.92], P =0.001) compared with medial therapy. Conclusions Compared with medical therapy, mitral surgery in patients with severe persistent or recurrent MR after TEER is associated with lower mortality despite the high‐risk profile of these patients. Patients with severe MR after TEER should be considered for surgery at a referral mitral surgical center.
Commentary: Resection of Giant Craniopharyngioma: Contending With Multiple Compartments and Myriad Perforating Arteries: 2-Dimensional Operative Video
Bocanegra‐Becerra, Jhon E. , Patra, Devi Prasad, Bathini, Abhijith , Nome, Marie A. Di , Phelps, Taylor, Nguyen, Brandon , Patra, Devi P. , Di Nome, Marie A, Bathini, Abhijith R , Phelps, Taylor, Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | October 17, 2022 | Volume: 23 | Issue: 6 | Pages: e411-e412

10.1227/ons.0000000000000457 | PMID 36251415 Get It

Platelet‐rich plasma versus corticosteroid injections in the management of patients with rotator cuff disease: A systematic review and meta‐analysis
Adra, Maamoun , Ghazal, Nour El , Nakanishi, Hayato , Smayra, Karen , Hong, Sam S., Miangul, Shahid , Than, Christian A., Tennent, Duncan , Than, Christian A. , Matar, Reem H, Than, Christian A , Than, Christian A , El Ghazal, Nour , Matar, Reem

Mayo Clinic

Journal of Orthopaedic Research | October 17, 2022 | Volume: 41 | Issue: 1 | Pages: 7-20

10.1002/jor.25463 | PMID 36250611 Get It

AbstractPlatelet‐rich plasma (PRP) is an alternative to corticosteroid (CS) injections in managing rotator cuff disease. This meta‐analysis investigated differences between PRP and CS for function and pain scores in significance and minimal clinical important difference (MCID). A literature search of Ovid Cochrane Library, Medline, Embase, Epub, and Scopus was conducted from inception to October 28, 2021. Eligible studies reported patients older than 18 years with a diagnosis of rotator cuff disease. This review was registered in PROSPERO (ID: CRD42021278740). Twelve studies met eligibility criteria (n = 639) of patients receiving either PRP or CS. At short‐term follow‐up, a difference favored CS compared to PRP in baseline change for disability of arm, shoulder, and hand (DASH) score (MD = −5.08, 95% CI: −8.00, −2.15; p = 0.0007; I2 = 0%) and simple shoulder test (SST) (MD = 1.25, 95% CI: 0.33, 2.18; p = 0.008; I2 = 0%). At intermediate follow‐up, a difference favored PRP to CS baseline change of the DASH score (MD = 3.41, 95% CI: 0.67, 6.15; p = 0.01; I2 = 0%). At medium‐term, a difference favored PRP to CS baseline change of the American Shoulder and Elbow Surgeons Shoulder (ASES) score (MD = −4.42, 95% CI: −8.16, −0.67; p = 0.02; I2 = 0%). Both treatments achieved individual MCID for each score. Despite favoring CS at short‐term follow‐up and PRP at intermediate‐ and medium‐term follow‐up, functional and pain scores did not demonstrate any clinical difference between the two treatment modalities in management of rotator cuff disease at all follow‐up periods.
Perioperative Circulatory Support and Management for Lung Transplantation: A Case-Based Review
Liang, Hong , Fritz, Ashley V, Martin, Archer K, Fritz, Ashley Virginia , Martin, Archer Kilbourne

Mayo Clinic

Seminars in Cardiothoracic and Vascular Anesthesia | October 17, 2022 | Volume: 27 | Issue: 1 | Pages: 68-74

10.1177/10892532221134574 | PMID 36250808 Get It

Lung transplantation (LTx) historically was performed with cardiopulmonary bypass (CPB) or Off-pump. Recent data suggest an increased interest in extracorporeal membrane oxygenation (ECMO) as perioperative circulatory support by many lung transplantation centers worldwide. However, there are no established guidelines for anesthetic management for LTx. We present a patient with a history of systemic sclerosis and interstitial lung disease complicated by acute onset of systemic pulmonary hypertension and right heart failure undergoing LTx. We aim to discuss perioperative circulatory support, including ECMO bridge to LTx, and how best to consider the varied intraoperative strategies of CPB vs ECMO vs off-pump during LTx, intraoperative maintenance, and coagulation management.
Up, up and away! Atrial septal pouch thrombus: an unexpected encounter during transeptal puncture
Ripoll, Juan G. , Padang, Ratnasari , Luis, Sushil Allen , Alkhouli, Mohamad

Mayo Clinic

No container title available | October 17, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166601377.75405016/v1 Get It

Atrial septal pouch is a common anatomic variant of the interatrial septum and a nidus for thrombus formation. Left-sided atrial septal pouch has been associated with an increased risk of cryptogenic stroke. We described a case of left-sided atrial septal pouch thrombus, incidentally found prior to transseptal puncture during Watchman device placement. This case highlights the importance of a thorough echocardiographic evaluation of the atrial septum prior to transseptal access and recognition of this finding as a potential cardiac source of embolism.
Echocardiographic Assessment of Prosthetic Valves
Freeman, William K., Ashraf, Hasan

Mayo Clinic

Reviews in Cardiovascular Medicine | October 17, 2022 | Volume: 23 | Issue: 10 | Pages: No page available

10.31083/j.rcm2310343 | PMID 39077122 Get It

Prosthetic valves are increasingly encountered in clinical practice. A grasp of the intricacies of the assessment and management of prosthetic valves is thus a crucial skillset for the practicing cardiologist. Echocardiography is the imaging modality of choice for the anatomic and functional evaluation of prosthetic valve. This document reviews the general features of prosthetic valves, echocardiographic identification of normally functioning and dysfunctional prosthetic valves as well as echocardiographic diagnosis of specific prosthetic valvular abnormalities.
Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
Brucato, Antonio , Lim-Watson, Michelle , Klein, Allan L. , Imazio, Massimo , Cella, David , Cremer, Paul , LeWinter, Martin M. , Lin, David , Lotan, Dor , Pancrazi, Massimo, Trotta, Lucia , Klooster, Brittany , Litcher‐Kelly, Leighann , Zou, Liangxing, Magestro, Matt , Wheeler, Alistair, Paolini, John F. , Abbate, Antonio , Abo‐Auda, Wael, Akhtar, Asif, Arad, Michael , Baibhav, Bipul, Bhalla, Karan, Cross, David, Eisen, Alon , FREEDBERG, NAHUM A., Fuchs, Shmuel, Gaddam, Eliyazar, Gelfand, Eli V. , Grena, Paul, Halabi, Majdi , Harris, David C.H. , Karim, Amin H., Kontzias, Apostolos , Kornberg, Robert, Latif, Faisal , Leibowitz, David , Lotan, Dor, Lim-Watson, Michelle Z , Klein, Allan , Luis, Sushil A , Lotan, Dor , Klooster, Brittany , Litcher-Kelly, Leighann , Paolini, John F , Brucato, Antonio , Cremer, Paul C , Imazio, Massimo , Luis, Sushil Allen , Atar, Shaul , Collins, Sean P. , Colquhoun, David Martin , Dwivedi, Girish , Gattorno, Marco , Insalaco, Antonella , Karim, Amin, Knowlton, Kirk U. , Lotan, Dor

Mayo Clinic

Journal of the American Heart Association | October 17, 2022 | Volume: 11 | Issue: 20 | Pages: No page available

10.1161/jaha.121.023252 | PMID 36250662 Get It

Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY (rilonacept inhibition of interleukin‐1 alpha and beta for recurrent pericarditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL‐1α and ‐β cytokine trap) in recurrent pericarditis. A secondary analysis of these data evaluated the patient‐reported outcome questionnaire score change during the trial. Methods and Results Participants completed 5 patient‐reported outcome (PRO) questionnaires assessing pericarditis pain, health‐related quality of life, general health status, sleep impact, and overall symptom severity. PRO score changes during the treatment run‐in period (12 weeks) and the blinded randomized withdrawal period (up to 24 weeks) were evaluated using descriptive statistics and mixed model repeated measures analyses. Participants with PRO data from the run‐in period (n=84) and the randomized withdrawal period (n=61; 30 rilonacept, 31 placebo) were included in analyses. Run‐in baseline PRO scores indicated that pericarditis symptoms during pericarditis recurrence impacted health‐related quality of life. All PRO scores significantly improved ( P <0.001) on rilonacept treatment during the run‐in period. For the randomized withdrawal period, PRO scores were maintained for participants receiving rilonacept. For those receiving placebo and who experienced a recurrence, PRO scores deteriorated at the time of recurrence and then improved following rilonacept bailout. At randomized withdrawal Week 24/End of Study, scores of participants who received bailout rilonacept were similar to those of participants who had continued rilonacept. Conclusions These results demonstrate the burden of pericarditis recurrences and the improved physical and emotional health of patients with recurrent pericarditis while on rilonacept treatment. These findings extend prior rilonacept efficacy results, demonstrating improvements in patient‐reported health‐related quality of life, sleep, pain, and global symptom severity while on treatment. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03737110.